Clinical Trial Update: Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating neoadjuvant sintilimab plus chemotherapy for resectable squamous cell non-small cell lung cancer is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Squamous Cell Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING